Generating destination analysis
Catalyst Play
Featured in “Three Biotech Stocks to Buy Before ASCO's Biggest Data Drop”
Recursion Pharmaceuticals uses AI to discover drugs at a fraction of traditional cost and time. Multiple clinical programs are reporting data at ASCO 2026. A single hit validates the entire AI drug discovery model — and Recursion has more shots on goal than anyone else in the space.
The catalyst: The American Society of Clinical Oncology (ASCO) annual meeting — May 29 to June 2 in Chicago — is the most important event in cancer drug development. Over 40,000 oncology professionals gather for late-stage clinical trial data presentations that routinely move biotech stocks 30–50% in a single session. These three companies have the most anticipated data readouts at ASCO 2026, and the results will determine their trajectory for years.
Compass Direction
Earnings IntelligenceAI-Powered
Compass Score
Unlock Full RXRX Analysis
UpgradeKey Numbers
Market Cap
$4B
P/E
N/A
Revenue Growth
+55.0%
Gross Margin
N/A
ROE
N/A
About Recursion Pharmaceuticals
Listed on the NASDAQ, Recursion Pharmaceuticals operates as a small-cap player in the biotech sector, offering investors focused access to biotech and genomics growth drivers. AI-driven drug discovery platform using machine learning to decode biology at scale. With a $4B market capitalization and no current profitability, the business is characterized by exceptional revenue growth, reporting +55% revenue change year-over-year.
Expert Coverage
Price & Technical Analysis
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
More in Biotech & Genomics
ARK Genomic Revolution ETF
ETF focused on companies advancing genomics, gene editing, and therapeutics.
DexCom Inc.
Continuous glucose monitoring leader expanding beyond diabetes management.
Alnylam Pharmaceuticals
RNA interference therapeutics leader with approved treatments for rare diseases.
Eli Lilly and Company
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.